The Clinicopathologic Significance of p53 and BAF250a (ARID1A) Expression in Clear Cell Carcinoma of the Endometrium

被引：0
|
作者：
Fadare, O.
Gwin, K.
Desouki, M. M.
Crispens, M. A.
Jones, H. W., III
Khabele, D.
Mohammed, K.
Liang, S. X.
Zheng, W.
Hecht, J. L.
Parkash, V.
机构：
[1] Vanderbilt Univ, Nashville, TN USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] UPMC, Pittsburgh, PA USA
[4] N Shore LIJ, Nhp, NY USA
[5] Univ Arizona, Tucson, AZ USA
[6] Harvard Univ, Boston, MA 02115 USA
[7] Yale Univ, New Haven, CT USA
来源：
LABORATORY INVESTIGATION | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1138
引用
收藏
页码：273A / 273A
页数：1
相关论文
共 50 条
  • [11] BAF250a (ARID1A) Combined with HNF-1b, ER and P53 Can Distinguish between Ovarian Clear Cell Carcinoma and Papillary Serous Carcinoma
    Xiao, W.
    Awadallah, A.
    Xin, W.
    MODERN PATHOLOGY, 2012, 25 : 301A - 301A
  • [12] Loss of BAF250a (ARID1A) Expression Is Associated with Progression of Endometriosis-Related Stage I Ovarian Clear Cell Carcinoma
    Kawabata, Ayako
    Kiyokawa, Takako
    Yanaihara, Nozomu
    Okamoto, Aikou
    LABORATORY INVESTIGATION, 2016, 96 : 290A - 290A
  • [13] Loss of BAF250a (ARID1A) Expression Is Associated with Progression of Endometriosis-Related Stage I Ovarian Clear Cell Carcinoma
    Kawabata, Ayako
    Kiyokawa, Takako
    Yanaihara, Nozomu
    Okamoto, Aikou
    MODERN PATHOLOGY, 2016, 29 : 290A - 290A
  • [14] The ARID1A, p53 and β-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
    Heckl, Marlene
    Schmoeckel, Elisa
    Hertlein, Linda
    Rottmann, Miriam
    Jeschke, Udo
    Mayr, Doris
    PLOS ONE, 2018, 13 (02):
  • [15] Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary
    Kato, Masafumi
    Takano, Masashi
    Miyamoto, Morikazu
    Sasaki, Naoki
    Goto, Tomoko
    Suzuki, Ayako
    Hirata, Junko
    Sasa, Hidenori
    Tsuda, Hitoshi
    Furuya, Kenichi
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 395 - 401
  • [16] ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts
    Wiegand, Kimberly C.
    Sy, Keiyan
    Kalloger, Steve E.
    Li-Chang, Hector
    Woods, Ryan
    Kumar, Aalok
    Streutker, Catherine J.
    Hafezi-Bakhtiari, Sara
    Zhou, Chen
    Lim, Howard J.
    Huntsman, David G.
    Clarke, Blaise
    Schaeffer, David F.
    HUMAN PATHOLOGY, 2014, 45 (06) : 1258 - 1268
  • [17] Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment
    Fadare, Oluwole
    Renshaw, Idris L.
    Liang, Sharon X.
    JOURNAL OF CANCER, 2012, 3 : 129 - 136
  • [18] ARID1A/BAF250a is significantly overexpressed in primary invasive breast cancer
    Szpon, Lukasz
    Agrawal, Anil
    Jelen, Michal
    Lipinski, Artur
    Rudnicki, Jerzy
    Makuch, Sebastian
    Wozniak, Marta
    Szmit, Mateusz
    Agrawal, Siddarth
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (06) : 3937 - 3945
  • [19] Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer
    Cho, Hanbyoul
    Kim, Jane Seon-Young
    Chung, Hyunsoo
    Perry, Candice
    Lee, Heejeong
    Kim, Jae-Noon
    HUMAN PATHOLOGY, 2013, 44 (07) : 1365 - 1374
  • [20] BAF250a (ARIDIA) Combined with HNF-1b, ER and P53 Can Distinguish between Ovarian Clear Cell Carcinoma and Papillary Serous Carcinoma
    Xiao, W.
    Awadallah, A.
    Xin, W.
    LABORATORY INVESTIGATION, 2012, 92 : 301A - 301A
12345